Baseline and on-treatment serum bicarbonate, intensive blood pressure lowering, and mortality: the Systolic Blood Pressure Intervention Trial (SPRINT)
Pareek M, Byrne C, Vaduganathan M, Biering-Sorensen T, Krogager M, Kragholm K, McCullough M, Desai N, Olsen M, Bhatt D. Baseline and on-treatment serum bicarbonate, intensive blood pressure lowering, and mortality: the Systolic Blood Pressure Intervention Trial (SPRINT). European Heart Journal 2020, 41: ehaa946.2731. DOI: 10.1093/ehjci/ehaa946.2731.Peer-Reviewed Original ResearchSystolic Blood Pressure Intervention TrialIntensive blood pressureSerum bicarbonate levelsBlood pressureBaseline bicarbonateBicarbonate levelsCV causesAntihypertensive treatmentSystolic blood pressure 130End-stage renal diseaseStandard antihypertensive treatmentHigh cardiovascular riskChronic kidney diseaseGlomerular filtration rateRisk of deathStandard blood pressureLow bicarbonate levelsYears of ageMultivariable adjustmentCardiovascular riskSerum bicarbonateRenal diseaseLaboratory variablesPrognostic implicationsIntervention trialsOutpatient Cost-effectiveness Study of Hyperkalemia Management
Desai N, Rowan C, Alvarez P, Fogli J, Coca S. Outpatient Cost-effectiveness Study of Hyperkalemia Management. Journal Of Cardiac Failure 2020, 26: s115. DOI: 10.1016/j.cardfail.2020.09.332.Peer-Reviewed Original ResearchOutpatient costsOptum's de-identified ClinformaticsEnd-stage renal diseaseMatched-cohort designData Mart DatabaseTreatment of hyperkalemiaMedicare Advantage populationCost-effectiveness studiesReal-world evidenceMEq/LCongestive HFHK cohortHyperkalemia managementPotassium bindersIndex dateCohort studyRenal diseaseOutpatient outcomesMean ageBaseline variablesInclusion criteriaPatiromerLarge cohortStudy populationCensoring event